secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2024-03-22T23:59:59+00:00
Accession:  0001140361-24-014809
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Eterna Therapeutics receives Nasdaq delisting notice for stockholders' equity below $2.5M minimum
--------------------------------------------------------------------------------

- Stockholders' equity was $2.2M as of Dec 31, 2024, below the $2.5M minimum required by Nasdaq Listing Rule 5550(b)(1).
- Company must submit a compliance plan to Nasdaq by May 3, 2024.
- If plan accepted, Nasdaq may grant up to 180-day extension to regain compliance.
- No immediate effect on listing; common stock continues trading under ERNA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000114036124014809/0001140361-24-014809-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000114036124014809/ef20024913_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-014809

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer